9th Annual Biomarkers Congress

View Profile


Pre/Non Reviewed Papers, Proceedings

Year Title Authors
1. 2010 Achieving pT0N0 at radical cystectomy: outcomes of 135 pT0N0 bladder cancer patients treated with radical cystectomy: the Canadian Bladder Cancer Network experience.
2. 2010 PT2-3N0M0 prostate cancer with positive and negative margins : clinical outcome and time to salvage radiotherapy.
3. 2010 Validation of residual pathologic stage at radical cystectomy as a prognostic factor in patients with cT2NO bladder cancer.
4. 2010 Is prostate-sparing during radical cystectomy advisable?
5. 2010 Urine measurement of TMPRSS2:ERG for the early detection of significant prostate cancer
6. 2010 AJCC TNM substaging of p72 bladder cancer : Is it necessary?
7. 2010 Disease-free survival at 2 or 3 years correlates with 5-year overall survival inpatients undergoing radical cystectomy for muscle-invasive bladder cancer.
8. 2010 Adjuvant chemotherapy for urothelial carcinoma of the urinary bladder
9. 2010 Radical cystectomy for clinically muscle invasive bladder cancer: does prior superficial disease affect clinical outcomes?
10. 2010 Stage-based approach to surveillance following radical cystectomy in bladder cancer patients
11. 2010 Disease outcome of 261 patients with a prostatic specific antigen (greater than or equal to) 20 mg/mL treated with radical prostatectomy at a single institution.
12. 2010 Copy number variation of sex-steroid metabolizing genes as biomarkers of prostate cancer recurrence after prostatectomy : looking at the end of the androgenic signal.
13. 2010 Urine measurement of TMPRSSE:ERG for the early detection of significant prostate cancer.
14. 2010 Risk-stratified surveillance guidelines following radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience.
15. 2010 Outcomes for patients with pT3-4 or pN+ bladder cancer treated with radical cystectomy: Canadian Bladder Cancer Network
16. 2010 Clinical outcome in patients with pT4 urothelial carcinoma at radical cystectomy.
17. 2009 Improved cancer specific-survival in patients with muscle-invasive bladder cancer expressing cyclo-oxygenase-2.
18. 2009 Grossman HB. La cystoscopie fluorescente apres instillation de hexaminolevulinate ameliore la detection et reduit les recidives precoces apres resection de tumeurs papillaires de la vessie
19. 2009 Evaluation de la tomography admission par positron couple au scanner [18F-FDG-PET/CT] dans le bilan dextension des tumeurs infiltrantes de la vessie
20. 2009 Etude immunohistochimique de la correlation entre l expression des sous-unites alpha-1 et alpha-3 de la pompe sodium/potassium et le pronostic du cancer de la prostate
21. 2009 Outcome of 2287 bladder cancer patients treated with radical cystectomy: the Canadian Bladder Cancer Network Experience.
22. 2009 Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level : long term follow up.
23. 2009 Etude de phase II : impact du raitement par inhibiteurs de la 5 alpha-reductase sur le cancer de prostate de bas grade
24. 2009 Flourescence cystoscopy with hexaminolevulinate (HAL) improves detection rate of Ta and T1 bvladder cancer and reduces recurrence following TURBT at nine months
25. 2009 Prognostic value of insulin-like growth factor-1 and binding proteins 2 and 3 in patients treated with radical prostatectomy
26. 2009 Fluorescence cystoscopy with Hexaminolevulinate (HAL) improves detection rate of Ta and T1 bladder cancer and reduces recurrence following TURBT at nine months
27. 2009 Surveillance guidelines based on recurrence patterns following radical cystectomy for bladder cancer: The Canadian Bladder Cancer Network Experience.
28. 2009 Prognostic value of insulin-like growth factor I and binding proteins 2 and 3 in patients treated with radical prostatectomy
29. 2009 Impact of adjuvant chemotherapy on outcomes for patients with pT3-4 or pN+ bladder cancer treated with radical cystectomy: Canadian Bladder Cancer Network.
30. 2009 Clinical and pathological stage correlations in patients with bladder carcinoma: Canadian Bladder Cangter Network experience.
31. 2009 Associations between age and clinical outcomes after radical cystectomy : results from the Canadian Bladder Cancer Network
32. 2009 Achieving pT0N0 at radical cystectomy: outcomes of 135 pT0N0 bladder cancer patients treated with radical cystectomy: the Canadian Bladder Cancer Network experience.
33. 2009 Expression and functionality of toll-like receptors in human urothelial cells.
34. 2009 Hexaminolevulinate fluorescence cystoscopy improves detection and resection of papillary bladder cancer lesions and reduces early recurrences
35. 2009 Outcome of 2287 bladder cancer patients treated with radical cystectomy: the Canadian Bladder Cancer Network experience.
36. 2009 Extent of lymphadenectomy and biochemical recurrence after radical prostatectomy: a multicentre study
37. 2009 Improved cancer specific-survival in patients with muscle-invasive bladder cancer expressing cyclo-oxygenase-2
38. 2009 Evaluation of fluorodeoxyglucose positron emission tomography associated with computed tomography (18F-FDG-PET/CT) imaging for staging of bladder transitional cell carcinoma.
39. 2009 Impact of histology on outcomes of radical cystectomy: a series from the Canadian Bladder Cancer Network
40. 2009 Outcome of 304 clinical T1G3 bladder cancer patients treated with radical cystectomy: the Canadian Bladder Cancer Network experience
41. 2009 Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of over 4300 patients
42. 2009 Urine assays for PCA3 and TMPRSS2:ERG gene fusion to predict the diagnosis of prostate cancer.
43. 2009 Evidence-based gender related outcomes after radical cystectomy: results of a large multicenter study
44. 2009 Contemporary outcomes of radical cystectomy in 2287 patients with transitional cell carcinoma of the bladder: a canadian multi-institutional experience.
45. 2009 Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
46. 2009 Hexaminolevulinate fluorescence cystoscopy improves detection and resection of papillary bladder cancer lesions and reduces early recurrences
47. 2009 Feasibility and clinical utility of a TMPRSS2:ERG gene fusion urine test
48. 2009 Evaluation of fluorodeoxyglucose positron emission tomography associated with computed tomography (18F-FDG-PET/CT)imaging for staging of bladder transitional cell carcinoma
49. 2009 Improved cancer specific-survival in patients with muscle-invasive bladder cancer expressing cyclo-oxygenase-2
50. 2009 Predictive value of the combination of immunohistochemical markers in patients with pt1 disease at radical cystectomy
51. 2009 Prognostic value of lymph node density in a multi-center, international cohort of patients with node positive urothelial carcinoma of the bladder.
52. 2009 Lymphovascular invasion is a powerful predictor of clinical outcomes in node-negative radical cystectomy patients: an international external validation study.
53. 2009 Improved prediction of clinical outcomes in patients with advanced bladder cancer using a panel of four cell cycle regulators
54. 2009 Extent of lymphadenectomy and biochemical recurrence after RP: a multicenter study
55. 2009 Phase II study of treatment with 5-alpha reductase inhibitors in low risk prostate cancer.
56. 2008 Extent of lymphadenectomy and biochemical recurrence after RP: a multicenter study
57. 2008 Treatment outcome of immediate versus delayed hormone therapy in patients with lymph node metastases following radical prostatectomy.
58. 2008 Salvage therapy with Bicalutamide 150 mg in patients with PSa failure under androgen deprivation for advanced prostate cancer
59. 2008 Multi-institutional evaluation ofo the predictive value of p53 immunohistochemical staining in patients with pT1-2 N0 disease at radical cystectomy
60. 2008 Impact of pelvic lymphadenectomy on disease-free survival after radical prostatectomy: a multicenter study.
61. 2008 Combination of cell cycle regulating bio-markers improves prognosis in patients with organ confined urothelial cancer at radical cystectomy
62. 2008 Phase II study of treatment with 5-alpha-reductase inhibitors (5ARIs) in low risk prostate cancer.
63. 2008 Frequency of cyclooxygenase-2 expression is increased in non-muscle invasive bladder tumors at higher risk of recurrence
64. 2008 Extended lymphadenectomy in radical prostatectomy: a multicenter study
65. 2008 Phase II study of treatment with 5-alpha reductase inhibitors (5ARIS) in low risk prostate cancer.
66. 2008 Phase II study of treatment with 5-alpha reductase inhibitors in low risk prostate cancer.
67. 2008 Bladder tumor infiltrating mataure dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy
68. 2008 Extended lymphadenectomy in radical prostatectomy: a multicenter study.
69. 2008 Phase II study of treatment with 5-alpha reductase inhibitors (5ARIS) in low risk prostate cancer
70. 2008 Multi-institutional validation of the predictive value of KI-67 labeling index in patients with urinary bladder cancer.
71. 2007 Salvage therapy with bicalutamide 150 mg in patients with PSA failure under LHRH therapy or surgical castration for advanced prostate cancer
72. 2007 Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human superficial bladder cancer
73. 2007 MAGE-A4 and MAGE-A9 protein expression in renal cell carcinoma.
74. 2007 Tn expression in localized high-risk prostate cancer
75. 2007 Disease outcome of patients with a PSA ≥ 20 ng/ml treated by radical prostatectomy: analysis of 185 patients
76. 2007 PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
77. 2007 The PCA3 score is independent of prostate gland volume, and can synergize with other patient information for predicting biopsy outcome
78. 2007 PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression
79. 2007 The PCA3 score is independent of prostate gland volume, and can synergize with other patient information for predicting biopsy outcome
80. 2007 Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with Bicalutamide 150 mg monotherapy in patients with prostate cancer
81. 2006 MAGE-A9 expression in bladder cancer.
82. 2006 Effects of systematic use of ureteral stent in renal transplantation
83. 2006 Prototype Aptimae PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer
84. 2006 Identification of a chimeric CD80/CD86 and STEAP antigen containing adenoviral vbector for therapeutic vaccin against prostate cancer
85. 2006 MAGE-A9 expression in bladder cancer
86. 2006 M344 as a prognostic marker in high-risk prostate cancer
87. 2006 Cycle-dependent response to maintenance BCG in high-risk superficial bladder cancer
88. 2006 Prototype Aptima® PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer
89. 2006 Predictors of survical for carcinomas of the upper urinary tract.
90. 2006 Aptimae PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer
91. 2006 APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
92. 2006 Prototype APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
93. 2006 Alterations of GLI1 & 2 transcription factors as a target for gene therapy of superficial papillary bladder tumors
94. 2006 Alterations of the Sonic hedgehog pathway in human superficial bladder cancer: loss of PTC and GLI expression
95. 2006 Disease outcome of patients with a PSA ≥20 treated by radical prostatectomy: analysis of 177 patients.
96. 2006 Effects of systematic use of ureteral stent in renal transplantation
97. 2005 The ratio of PCA3 to PSA mRNAs in urine is a better predictor of prostate biopsy results than the absolute copy level of PCA3 mRNA alone
98. 2005 Development and performance of the APTIMA POCA3 molecular urine test for prostate cancer
99. 2005 Aptima PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer
100. 2005 PCA3DD3 gene expression is a marker of prostate cancer
101. 2005 Alteration du sentier de Sonic Hedgehog/Patched dans les tumeurs superficielles de la vessie
102. 2005 Prospective, randomized and double-blind study comparing effects of Bupivacaine vs placebo after radical retropubic prostatectomy.
103. 2005 Effects of systematic use of ureteral stent in renal transplantation.
104. 2005 Assessment of the optimum dose of tamoxifen for the prophylaxis of bicalutamide-associated breast events
105. 2005 Adjuvant chemotherapy for node positive bladder cancer patients: influence of regimen on durability of response.
106. 2005 Expression of cyclooxygenase-2 is associated with stage, grade and recurrence-free survival in superficial bladder cancer.
107. 2005 Cigarette smoking increases the malignant potential of upper urinary tract tumors
108. 2005 Dual-kidney transplants from marginal donors: Functional and surgical outcomes.
109. 2005 Tissue factor expression as a prognosis factor in patients with muscle-invasive bladder cancer treated by radical cystectomy
110. 2005 Dual-kidney transplants as an alternative for marginal donors.
111. 2005 PCA3DD3 TM gene expression is a marker of prostate cancer
112. 2004 Bacteriologic profile of Studer orthotopic neobladders and the risk of urinary tract infection
113. 2004 La surexpression de la cyclo-oxygenase-2 est associee au stade, au grade ainsi qua la survie sans recidive des tumeurs de vessie superficielles Ta-T1
114. 2004 L expression du facteur tissulaire permet de predire les patients a risque de progression apres cystectomie pour neoplasie infiltrante de la vessie.
115. 2004 The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage Ta/T1 urothelial cancer in the urinary bladder.
116. 2004 The use or Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of carcinoma in situ of the urinary bladder.
117. 2004 Validation of the 2002 TNM staging system for upper urinary tract tumors
118. 2004 Smoking increases the malignant potential of upper urinary tract tumors
119. 2004 Insomnie chez les hommes ayant subi une prostatectomie radicale pour un cancer de la prostate.
120. 2004 Multicentre phase 2 trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01A).
121. 2004 IGFBP-2 is an independent predictor of prostate cancer survival that is modulated by androgen deprivation therapy
122. 2004 Risk factors for bladder cancer recurrence following urothelial carcinoma of the upper urinary tract. .
123. 2004 Bacteriologic profile of Studer orthotopic neobladders and the risk of urinary tract infection
124. 2004 Insulin-like growth factor binding protein 2 is an independant predictor of prostate cancer survival.
125. 2004 Risk factors for bladder cancer recurrence following urothelial carcinoma of the upper urinary tract.
126. 2004 Utility of routine urine cytology in the follow-up of patients with Studer orthotopic neobladders.
127. 2003 Multicenter study of the uPM3 test, a new molecular urine assay to detect prostate cancer
128. 2003 Bacteriologic profile of Studer orthotopic neobladders and the risk of urinary tract infection
129. 2003 Risk factars for bladder cancer recurrence following urothelial carcinoma of the upper urinary tract.
130. 2003 Overexpression of cyclooxygenase-2 is correlated with better prognosis in muscle invasive bladder cancer
131. 2003 Expression of cyclin D1 and cyclin E are not predictors of response to salvage radiotherapy after radical prostatectomy
132. 2003 Disease outcome of patients with a PSA<40 ng/ml treated by radical prostatectomy.
133. 2003 Multicenter study of the uPM3 test: a new molecular urine assay to detect prostate cancer
134. 2003 Maintenance of BCG in high-risk population of transitional carcinoma of the bladder: clinical outcome at 2 years.
135. 2003 The Patched/Sonic Hedgehog signalling pathway in bladder cancer
136. 2003 Cancer/testis gene expression in bladder cancer.
137. 2003 Biochemical-free survival after radical prostatectormy and salvage radiotherapy according to risk category.
138. 2003 Radical prostatectomy reduces prostate cancer mortality : a comparative analysis of Quebec and Swedish results
139. 2003 Cancer/testis gene expression in bladder cancer.
140. 2003 Expression of p21 cell-cycle protein is an independent redictor of resonse to salvage radiotherapy after radical prostatectomy.
141. 2003 Validation of the tissue-array technique and prognostic value of cycin E, p53, p21 and P27 in muscle invasive bladder cancer
142. 2003 Diagnosis and monitoring of badder tumours using ImmunoCyt/uCyt+ in routine clinical practiced monitoring
143. 2003 Radical prostatectomy reduces prostate cancer mortality: a comparatiave analysis.
144. 2003 High diagnostic accuracy of the uPM3 urine test: a new molecular assay for prostate cancer diagnosis
145. 2003 Incidence, histology and follow-up of unsuspected prostatic cancer in patients undergoing radical cystoprostatectomy for bladder cancer
146. 2003 Tissue-arrays of invasive bladder cancer : validation of the technique and prognostic value of cyclin E, p53, p21 and p27 by immunohistochemical analysis.
147. 2003 Diagnosis and monitoring of badder tumours using ImmunoCyt/uCyt+ in routine clinical practiced monitoring.
148. 2003 l activateur MT1-MMP et l inhibiteur TIMP-2 dans le cancer de la prostate
149. 2002 Performance clinique du test uPM3: un nouveau test moleculaire pour la detection du cancer de la prostate
150. 2002 Impact sur la continence de l'ablation precoce de la sonde vesicale apres prostatectomie radicale.
151. 2002 Perte d'rozygotie de marqueurs microsatellites de la region 9q12-q22.31 dans le cancer superficiel de la vessie
152. 2002 Evaluation de la technique a haut rendement de tissue-array pour letude de marqueurs tumoraux dans le cancer infiltrant de la vessie
153. 2002 Perte d heterozygotie de marqueurs microsatellites de la region 9q12-q22.31 dans le cancer superficiel de la vessie
154. 2002 Evaluation de la technique a haut rendement de  tissue-array pour letude de marqueurs tumoraux dans le cancer infiltrant de la vessie
155. 2002 Multicenter study of the uPM3 test, a new molecular urine assay to detect prostate cancer
156. 2002 Overexpression of cyclooxygenase-2 is correlated with better prognosis in muscle invasive bladder cancer
157. 2002 Valeur predictive des proteines du cycle cellulaire p53, p21 et p27KIPI pour la reponse à la radiotherapie de rattrapage apres echec a la prostatectomie radicale
158. 2002 Clinical performance of the uPM3 test: a new molecular urine assay to detect prostate cancer
159. 2002 Neo-adjuvant androgen deprivation and radiotherapy for the treatment of biochemical failure post radical prostatectomy.
160. 2002 Optimal treatment aproach in patients with seminal vesicle invasion undergoing primary radical prostatectomy
161. 2002 Safety and outcome of early catheter removal following open radical prostatectom
162. 2002 Multicenter study of the uPM3 test, a new molecular urine assay to detect prostate cancer
163. 2002 Nasogastric tube use following radical cystectomy.
164. 2002 Neo-adjuvant androgen deprivation and radiotherapy for the treatment of biochemical failure post-radical prostatectomy
165. 2002 Safety and outcome of early catheter removal following radical prostatectomy.
166. 2002 Optimal treatment approach in patients with seminal vesicle invasion undergoing primary radical prostatectomy
167. 2002 Decreased p27 and cyclin E protein expression are factors of poor prognosis factors in patients treated by radical cystectomy for muscle invasive bladder cancer
168. 2002 Overexpression of cyclooxygenase-2 is correlated with poor prognosis in muscle invasive bladder cancer
169. 2002 Urinary PSA, a potential useful marker when serum PSA is between 4 and 10 ng/ml.
170. 2002 Early detection of local recurrence by urinary PSA.
171. 2002 Murine monoclonal anti-idiotype antibodies as surrogate antigens for 19A211, a sialylated carbohydrate antigen associated with superficial bladder cancer
172. 2002 Genetic studies on the etiology of superficial papillary bladder cancer and molecular basis for cancer vaccines
173. 2002 Valeur predictive des proteines du cycle cellulaire p53, p21 et p27KIPI pour la reponse a la radiotherapie de rattrapage apres echec a la prostatectomie radicale
174. 2001 Treatment outcome of immediate short term versus continuous or delayed hormone therapy in patients with node positive prostate cancer treated by radical prostatectomy.
175. 2001 dans la cancerogenese de la vessie.
176. 2001 Cell cycle markers p53 and p27K1P1 and DNA ploidy as prognostic markers in node positive prostate cancer patients treated by prostatectomy
177. 2001 Duration of neoadjuvant androgen deprivation therapy prior to radical prostatectomy and disease-free survival in men with prostate cancer.
178. 2001 Methods to improve efficacy of intravesical mitomycin C. : results of a phase III trial.
179. 2001 Treatment outcome of immediate short term versus continuous or delayed hormone therapy in patients with node positive prostate cancer treated by radical prostatectomy.
180. 2001 Treatment outcome of immediate short term versus continuous or delayed hormone therapy in patients with node positive prostate cancer treated by radical prostatectomy.
181. 2001 Timing of androgen deprivation therapy and prostate cancer survival. .
182. 2001 L utilisation systematique du tube naso-gastrique est-elle justifie a  la suite d une cystectomie radicale?
183. 2001 La radiotherapie de sauvetage precedee de 3 mois da hormonotherapie pour une elevation du PSA apres prostatectomie radicale
184. 2001 Preliminary results of the new urine test uPM3 for the diagnosis of prostate cancer.
185. 2001 Stromelysin-3 overexpresion by stromal cells predicts PSA failure in lower grade prostate cancer.
186. 2001 Le traitement par blocage androgenique de court terme versus l hormonotherapie continue: etude de la survie sans progression biochimique chez des patients atteints de cancer prostatique avec metastases ganglionnaires traites par prostatectomie radicale
187. 2001 Utilisation du test ImmunoCytTM de routine pour le diagnostic et le suivi des tumeurs transitionelles de la vessie
188. 2000 Histopathologie de la cystite interstitielle
189. 2000 Interet du phenotype p53, MDM2, p21 dans letude des mecanismes de la carcinogenese vesicale.
190. 2000 Neoadjuvant hormonotherapy upregulates IGF-1 and IGFBP-3 serum levels in patients with prostate cancer.
191. 2000 Insulin-like growth factor binding protein-3 and prostate cancer prognosis: a prospective study.
192. 2000 NRAMP1 polymorphisms and response to BCG immunotherapy in superficial bladder cancer
193. 2000 Significance of cyclin-dependent kinase inhibitor P27(K1P1) expression in superficial bladder tumors
194. 2000 Predictive value of cell cycle markers p53, MDM2, p21 and Ki-67 in superficial bladder tumor recurrence.
195. 2000 Tumorigenic pathways in low stage bladder cancer based on p53, MDM2 and p21 phenotypes
196. 2000 IGF-1 and IGFBP-3 serum levels in patients with prostate cancer : effects of neoadjuvant hormonotherapy and relation to clinical outcome after radical prostatectomy
197. 2000 Loss of heterozygosity of chromosome 9Q in superficial bladder cancer.
198. 2000 Transitional cell carcinoma of the renal pelvis and ureters: a review of 153 cases
199. 2000 Complications uriologiques dans la transplantation renale: linfluence du catheter ureteral
200. 2000 Tumorigenic pathways in low stage bladder cancer based on p53, MDM2 and p21 phenotypes.
201. 2000 Timing of palliative hormonal therapy and prostate cancer survival.
202. 2000 BMP-6 expression and risk of bone metastasis in advanced prostate cancer treated by prostatectomy.
203. 1999 P27 expression in patients with stage pT3 prostate cancer and PSA failure following radical prostatectomy.
204. 1999 Development of a bladder cancer vaccine based on M344, a mucin-associated carbohydrate antigen
205. 1999 Expression of p21 predicts psa failure in locally advanced prostate cancer treated by prostatectomy.
206. 1999 Dietary fat and prostate cancer progression and survival.
207. 1999 Dietary fat and prostate cancer progression and survival.
208. 1999 Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy
209. 1999 Influence de la nutrition sur la survenue et la progression du cancer de la prostate.
210. 1999 Risk of incidental prostate cancer associated with precancerous lesions.
211. 1999 Neoadjuvant hormonal therapy and risk of PSA failure after radical prostatectomy
212. 1999 Timing of palliative hormonal therapy and prostate cancer survival.
213. 1999 Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy.
214. 1999 Tumor markers and their role in management of bladder cancer
215. 1999 Surgical complications in kidney transplantation : a review of the last 485 transplants at CHUQ, Pavillon Hotel-Dieu de Quebec
216. 1998 Dietary fat and prostate cancer progression and survival
217. 1998 Chromosome 9 deletions and recurrence of superficial bladder cancer: evidence for two novel tumor suppressor regions on the long arm
218. 1998 Blood management in radical prostatectomy: Quebec experience
219. 1998 BMP-6 expression and risk of bone metastasis in advanced prostate cancer treated by prostatectomy.
220. 1998 Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy.
221. 1998 Antibiotic therapy for chronic inflammatory (NIH category II/IIIA) prostatistis
222. 1998 Evaluation of a monoclonal antibody test for the detection of superficial bladder cancer: ImmunocytTM.
223. 1998 Differential expression of p21 and p53 proteins on primary bladder carcinoma versus lymph nodes metastasis and relationship with adjuvant chemotherapy response.
224. 1998 DiagnoGene P A3 reliable NASBA based reagents for detecting PCA3 mRNA, a recently described prostate marker.
225. 1998 Expression of p21 peut predire la recidive chez les patients avec le cancer de la prostate localement avance (pT3) traites par prostatectomie radicale
226. 1998 Association entre le niveau de depense Enertique au travail et le cancer de la prostate.
227. 1998 Facteurs nutritionnels associes aux lesions precancereuses de la prostate
228. 1998 Les derives du sang et la prostatectomie radicale : l experience de Quebec
229. 1998 Prognostic valule of p21 and p53 protein expression on autologous primary and metastatic bladder cancer.
230. 1998 Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy.
231. 1998 Evaluation of a monoclonal antibody test for the detection of superficial bladder cancer: ImmunocytTM.
232. 1998 Antibiotic therapy for chronic inflammatory (NIH category II/IIIA) prostatis.
233. 1998 Blood management in radical prostatectomy: Quebec experience
234. 1998 L expression des proteines p21 et p53 peuvent predire la reponse a la chimiotherapie adjuvante (MVAC) dans les tumeurs invasives de la vessie avec metastases ganglionnaires.
235. 1997 Optimided microvessel density is associated with recurrence.
236. 1997 Placebo therapy in benign prostatic hyperplasia
237. 1997 A phase III, randomized, double-blind, placebo-controlled, multicenter trial, comparing interferon gamma to placebo in patients with metastatic renal cell carcinoma (RCC).
238. 1997 High sensitivity of ImmunoCytTM for the detection of bladder cancer: a Canadian multicenter study.
239. 1997 24th Congress of the SIU
240. 1997 A phase III, randomized, double-blind, placebo-controlled, multicenter trial comparing interferon gamma to placebo in patients with metastatic renal cell carcinoma (RCC).
241. 1997 Bladder cancer screening in an occupatioally exposed cohort: implications for bladder cancer management.
242. 1997 Alternative anesthesia techniques for transurethral biopsy and resection of bladder tumours
243. 1997 Assessment of quality of life after radical cystectomy: comparison between patients with an ileal conduit and a continent urinary reservoir
244. 1997 A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 month post-treatment PSA results
245. 1997 LiazalTM (Liarozole) versus cyproterone acetate in advanced prostate cancer: results of a randomized phase III trial
246. 1997 Electromotive drug administration (EMDA) of lidocaine as an alternative anestheisa for tansurethral surgery
247. 1997 Is there a role for aggressive treatment of high risk localized prostate cancer?
248. 1997 Electromotive drug administration (EMDA) of lidocaine as an alternative anesthesia for transurethral surgery.
249. 1997 An evaluation and characterization of men diagnosed with chronic prostatis of an inflammatory nature
250. 1997 A CUOG phase III, randomized, double-blind trial comparing interferon gamma to placebo in patients with metastatic renal cell carcinoma (mRCC).
251. 1997 Neoadjuvant androgen ablation prior to radical prostatectomy (CUOG P-92): 24 month post-treatment PSA results
252. 1997 Orthotopic bladder reconstruction in women.
253. 1997 Is there a role for aggressive treatment of high risk localized prostate cancer?
254. 1997 Assessment of quality of life after radical cystectomy: comparison between patients with an ileal conduit and a continent urinary reservoir
255. 1996 Localisation lymphoscintigraphique des ganglions lymphatiques pelviens chez les hommes porteurs dun cancer de la prostate localise.
256. 1996 Valeur pronostique de l expression des genes suppresseurs p53 et RB et de l ¢oncoene MDM2 chez les patients avec tumeur infiltrante de la vessie traites par chimiotherapie adjuvante de type MVAC.
257. 1996 The M344 monoclonal antibody recognizes a glycosylated form of the MUC2 mucin in human bladder cancer
258. 1996 A CUOG Phase III, randomized,double-blind trial comparing interferon gamma to placebo in patients with metastatic renal cell carcinoma (RCC).
259. 1996 Evaluation de la qualite de vie apres une cystectomie radicale: comparaison entre les patients ayant un conduit ileal et un reservoir urinaire continent
260. 1996 Amelioration de la detection des cancers de la vessie par immunocytologie avec anticorps monoclonaux
261. 1996 Dietary polyunsaturated fatty acids and prostate cancer.
262. 1996 Placebo therapy in benign prostatic hyperplasia.
263. 1996 Lymphoscintigraphic localization of pelvic lymph nodes in men with localized prostate cancer.
264. 1996 An algorithm to determine the prognosis of patients with primary superficial Ta and T1 bladder cancer.
265. 1996 Prognostic value of p53 overexpression in invasive bladder cancer patients treated by adjuvant MVAC
266. 1996 Influence of neoadjuvant hormonotherapy on PSA response and pathological stage at radical prostatectomy
267. 1996 Improved detection of bladder cancer by immunocytology with monoclonal antibodies M344 and 19A211
268. 1996 Intermediate end-point biomarkers in management of bladder cancer
269. 1996 Prognosis of infiltrating bladder cancer according to bladder replacement with ileal conduit or continent neobladder
270. 1996 Influence of neoadjuvant hormonotherapy on PSA response and pathological state at radical prostatectomy
271. 1996 Genetic anomalies in human bladder cancer.
272. 1995 Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer
273. 1995 Effets a long terme du finasteride versus le placebo dans le traitement des patients atteints de symptomes moderes d hyperplasie benigne de la prostate (HBP).
274. 1995 Diagnostic et monitoring du cancer de la vessie par immunocytologie sur lavage vesical
275. 1995 Les examens cytologiques et par cytometrie de flux sont-ils utiles dans le diagnostic des tumeurs vesicales?
276. 1995 Valeur de la radiotherapie pre-operatoire et de la chimiotherapie adjuvante dans le traitement du cancer de la vessie infiltrant traite par cystectomie radicale
277. 1995 Influence du mode de remplacement vesical par conduit ou neo-vessie continente sur le pronostic des cancers vesicaux infiltrants traites par cystectomie radicale
278. 1995 Facteurs pronostiques dans le cancer de la vessie infiltrant traite par cystectomie radicale
279. 1995 La pertinence de la surrenalectomie dans le traitement chirurgical de l'adenocarcinome renal
280. 1995 Definition of a new mucin antigen (MAUB-1) associated with human superficial bladder cancer.
281. 1995 Cystite chronique debilitante induite par l'acide tiaprofenique (Surgam) un agent anti-inflammatoire non stedien
282. 1995 Long-term effects of finasteride vs placebo in the treatment of patients with moderate symptoms of benign prostatic hyperplasia (BPH).
283. 1995 Influence de l'hormonotherapie neoadjuvante et de la reponse de l'APS sur le stade pathologique du cancer de la prostate trait chirurgicalement
284. 1995 Influence of urinary diversions by conduits or continent reservoirs on the prognosis of infiltrating bladder cancer treated by radical cystectomy
285. 1995 Influence of preoperative radiotherapy and adjuvant chemotherapy on survival of bladder cancer patients treated by radical cystectomy
286. 1995 Immunocytology of the diagnosis and monitoring of human bladder cancer
287. 1995 Urinary incontinence after radical prostatectomy: Can it be predicted?
288. 1995 The safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia: a randomized, double-blind multicentre canadian study.
289. 1995 Identification de facteurs pouvant favoriser l'incontinence post-prostatectomie radicale.
290. 1994 Androgen-Receptors in normal prostate and prostatic carcinoma following neoadjuvant hormone therapy
291. 1994 Prevalence and clinical significance of Her-2/neu, P53 and Rb expression in primary superficial bladder cancer
292. 1994 Prognostic significance of nuclear DNA content and S phase fraction by flow cytometry in primary superficial bladder cancer
293. 1994 Effect of neoadjuvant endocrine therappy (total androgen blockade) on normal prostate and prostatic carcinoma: a randomized study.
294. 1994 DNA-Ploidy of transitional cell carcinoma from archival tissue: comparison of flow cytometry and image analysis
295. 1994 Detection of human papillomavirus by polymerase chain reaction in prostate cancer tissue.
296. 1994 Neoadjuvant antiandrogen therapy for localized prostate cancer
297. 1994 Significant effect of short-term hormonotherapy on prostatic intra-epithelial neoplasia (PIN) at radical prostatectomy: a randomized study
298. 1994 Prognostic implications of family history and mode of diagnosis on stage of prostate cancer at diagnosis.
299. 1994 Multidimensional scaling, a tool for the study of large panel of monoclonal antibodies against neoplasms
300. 1994 A monoclonal antibody defining the core protein of MAUB-1 (Mucin antigen of the urinary bladder).
301. 1994 Family history of prostate cancer and mode of diagnosis of prostate cancer in relation to stage at time of diagnosis
302. 1994 Diagnostic and prognostic value of the bladder tumor-associated mucin MAUB-1: results of multicenter clinical studies
303. 1994 Orthotopic bladder reconstruction after radical cystectomy in men and women.
304. 1994 Biomarkers in monitoring for efficacy of BCG and chemoprevention of bladder cancer with DMSO.
305. 1994 Two years of treatment with finasteride after radical prostatectomy.
306. 1994 Local immunological response following intra-vesical bacillus calmette Guerin (BCG) prophylaxis for bladder cancer.
307. 1994 Expression of tumor associated antigens in normal mucosa of bladder tumor patients.
308. 1994 Prognostic significance of tumor associated antigens M344 and 19A211 expression in Ta bladder cancer.
309. 1994 Prevalence and clinical significance of p53, Rb and HER-2/neu expression in newly diagnosed superficial bladder tumors
310. 1994 Tumor-associated antigens as prognostic factors for early recurrence of superficial pTa/pT1 bladder tumors
311. 1994 Les examens cytologiques et par flux cytometrie sont-ils utiles dans le diagnostic des tumeurs vesicales?
312. 1994 Histoire familiale et mode de diagnostic en relation avec le stade du cancer de la prostate: Etude prospective cas-temoin
313. 1994 Valeur de la radiotherapie pre-operatoire et de la chimiothrapie adjuvante dans le traitement du cancer de la vessie infiltrant traite par cystectomie radicale
314. 1994 Facteurs pronostiques dans le cancer de la vessie infiltrant traite par cystectomie radicale
315. 1994 Valeur du PSA pour detecter un cancer chez les patients traites pour hypertrophie benigne de la prostate.
316. 1994 Influence du mode de remplacement vesical par conduit ou neo-vessie continente sur le pronostic des cancers vesicaux infiltrants traites par cystectomie radicale
317. 1994 Local immunological response following intravesical Bacillus Calmette-Guerin prophylaxis for bladder cancer
318. 1994 La pertinence de la surrenalectomie dans le traitement chirurgical de l adenocarcinome renal.
319. 1994 Identification de facteurs pouvant favoriser l'incontinence post-prostatectomie radicale.
320. 1993 Preliminary results of a prognostic study on tumoral antigens and recurrence among a cohort of 387 patients with resected primary superficial bladder tumors.
321. 1993 Effets benefiques d une hormonotherapie combinee neo-adjuvante pre-prostatectomie radicale dans le cancer prostatique localise. .
322. 1993 Improved detection and follow up of bladder tumors using immunocytology: a pilot study.
323. 1993 Prognostic factors in the treatment of localized prostatic cancer
324. 1993 Preliminary results of a prognostic study on tumoral antigens and recurrence among 387 patients enrolled at first resection of superficial bladder tumors.
325. 1993 Preliminary results of a prognostic study on tumoral antigens and recurrence among 387 patients enrolled at first resection of superficial bladder tumors.
326. 1993 Prognostic factor in the treatment of localized prostatic cancer
327. 1993 Effect of finasteride on patients with elevated PSA following radical prostatectomy for prostate cancer.
328. 1993 Beneficial effect of combination therapy administered prior to radical prostatectomy.
329. 1993 Molecular cloning of a highly glycosylated tumor-associated antigen of superficial papillary bladder tumors
330. 1993 Combined markers for bladder cancer risk assessment in exfoliated and biopsy cells.
331. 1993 Mapping of bladder tumorigenesis with biochemical markers
332. 1992 Analyse de la plodie (contenu cellulaire en ADN) du carcinome transitionnel de la vessie; comparaison entre la cytometrie de flux et la cytometrie statique.
333. 1992 Facteurs pronostiques et stades pathologiques des cancers de la prostate traites par chirurgie.
334. 1992 Evaluation fonctionelle des reconstructions vesicales post-cystectomies radicales.
335. 1992 Adjuvant MVAC chemotherapy after radical cystectomy for invasive bladder cancer
336. 1992 HMBA enhancement of cisplatin sensitivity in transitional cell carcinoma.
337. 1992 Clinical potential of simultaneous analysis of ploidy, Ki-67, T43 antigen and EGFR by flow cytometry in bladder cancer
338. 1992 Hexamethylene bisacetamide in the differentiation of human bladder tumor cells.
339. 1992 Human papilloma virus in human bladder cancer
340. 1992 Tumor associated antigens and epidermal growth factor receptor (EGFR) as prognosis tools for transitional cell carcinoma (TCC) of the bladder
341. 1992 Expression des oncogenes P53 et Neu dans le carcinome transitionnel superficiel de la vessie.
342. 1992 Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells.
343. 1992 Expression of different mucins in human superficial papillary bladder tumors
344. 1992 Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder.
345. 1992 Adjuvant MVAC chemotherapy after radical cystectomy for invasive bladder cancer.
346. 1992 Influence of the diagnostic modality, PSA level and neo-adjuvant therapy on pathological stage of prostatic carcinoma treated by radical surgery
347. 1992 P300 tumor associated antigen as a marker for bladder cancer detection.
348. 1992 Mapping of multiple biochemical markers to define field disease in bladder cancer
349. 1992 Biochemical characteristics and immunotherapeutic potential of a human epithelial mucin of superficial transitional cell bladder carcinoma.
350. 1991 In vitro differentiation of a human transitional cell carcinoma - a wolf in sheep's clothing?
351. 1991 Monitoring and prognostic determination of bladder tumors by flow cytometry with monoclonal antibodies on bladder irrigations
352. 1991 Correlation of DNA analysis and 19A211 antigen expression with response to BCG/IL2 immunotherapy.
353. 1991 Biochemical field disease in patients with transitional cell carcinoma
354. 1991 Toward intravesical immunotherapy of superficial bladder cancer. Sixth International Conference on Monoconal Antibody immunoconjugates for cancer
355. 1991 Valeur pronostique des marqueurs proliferatifs analyases en flux-cytometrie dans les cancers vesicaux
356. 1991 Immunocytologie par filtre pour la detection et le suivi des tumeurs vesicales
357. 1991 Prostatectomie radicale: influence du mode de detection et de la therapie adjuvante sur le stade pathologique.
358. 1991 Diagnostic et suivi du cancer de la vessie par flux-cytometrie utilisant des anticorps monoclonaux
359. 1990 Neoadjuvant hormonal therapy in the management of stage B2-C carcinoma of the prostate.
360. 1990 Slit-scan flow cytometry in the management of bladder cancer.
361. 1990 Establishing the reactivity of monoclonal antibodies for use in diagnosing and predicting outcomes of bladder cancer.
362. 1990 Immunopathological analysis of two new tumor associated antigens of human superficial bladder tumors.
363. 1990 Chimiotherapie adjuvante, type MVAC et indicateur pronostique d'un cancer de la vessie infiltrant
364. 1990 Partial characterization of the human tumor-associated mucin (MAUB-1) from the urinary bladder carcinoma.
365. 1990 Disease aggressiveness in advanced prostate cancer. 2nd International Symposium on GnRH Analogues in Cancer and Human Reproduction
366. 1990 Etude multicentrique sur l efficacite du traitement combine dans le cancer metastatique de la prostate.
367. 1990 Preservation vesicale fonctionnelle par enterocytoplastie de remplacement apres cystectomie radicale
368. 1990 Hormonotherapie neo-adjuvante dans le traitement des cancers de la prostate, stade B2-C.
369. 1990 Interet des marqueurs proliferatifs dans l analyse des tumeurs vesicales.
370. 1990 Adjuvant MVAC chemotherapy and prognostic indicators in invasive bladder cancer.
371. 1990 Functional bladder preservation by replacement enterocystoplasty after radical cystectomy.
372. 1990 Prognostic factors in invasive bladder cancer and early results of adjuvant M-VAC chemotherapy.
373. 1990 Expression of the T-138 antigen and survival of patients with bladder cancer.
374. 1989 A randomized trial of total androgen ablation vs orchiectomy in patients with metastatic prostatic cancer.
375. 1989 New patient data recording and analysis methods using computers and snomed.
376. 1989 Slit-scan flow cytometry in the management of bladder cancer
377. 1989 Total androgen blocade vs castration for treatment of metastatic cancer of prostate: a clinical randomized trial.
378. 1989 Immuno-gold labeling of bladder cancer associated antigens
379. 1989 Impact of non invasive imaging modalities on the diagnosis of renal tumors: the dilemma of masses 3 cm or less.
380. 1989 Comparative results of tubularized and detubularized replacement enterocystoplasty after radical cystoprostatectomy for cancer
381. 1989 Multicentre computerized patient records used for large scale clinical research and snomed coding
382. 1989 Variable modulation of expression of two superficial human bladder tumor associated antigens by spatial configuration of cell populations
383. 1989 Comparison of staining pattern of 15 different monoclonal antibodies (mab) directed against bladder tumor associated antigens of transitional cell carcinoma (TCC) of the bladder -A cooperative study.
384. 1988 Replacement enterocystoplasty after radical surgery for bladder cancer: functional assessment over time
385. 1988 In vivo and in vitro induction of specific antigens of human papillary superficial bladder tumors.
386. 1988 Improved detection and pronostic determination of bladder tumors by multiparameter flow cytometry with monoclonal antibodies
387. 1988 Canadian multicenter randomized double-blind study of castration with placebo or Anandron in metastatic cancer of prostate
388. 1988 Complications urologiques en transplantation renale: Etude comparative avant et depuis lre de la cyclosporine.
389. 1988 Resultats compares des remplacements vesicaux tubularises et non-tubularises apres cystectomie radicale
390. 1988 Masses renales malignes ou benignes: impact de l imagerie non-invasive sur les circonstances du diagnostic et le pronostic
391. 1988 L implant diode radioactif dans le traitement du cancer localise de la prostate: Y a-t-il un avantage.
392. 1988 Flow cytometry in the clinical management of bladder tumors: limits of DNA analysis and improved detection and pronostic determination with monoclonal antibodies
393. 1987 Monoclonal antibody defined tumor markers in the clinical management of urothelial neoplasia.
394. 1987 Total androgen blockade for metastatic cancer of prostate.
395. 1987 Total androgen blockade for metastatic cancer of prostate
396. 1987 New monoclonal antibodies to transitional cell carcinoma with specificity for low grade tumors.
397. 1987 Enterocystoplastie de remplacement apres chirurgie radicale pour cancer de la vessie: un premier recul.
398. 1987 Total Androgen blockade for metastatic cancer of the prostate.
399. 1987 Simultaneous purification of two growth-regulated surface glycoproteins of human bladder cancer.
400. 1987 Growth-regulated surface glycoproteins of human bladder cancer: Flow cytometry study with monoclonal antibodies
401. 1987 Localization of human bladder tumor xenografts in nude mice with radiolabeled monoclonal antibodies.
402. 1986 Multiparameter flow cytometry with monoclonal antibodies to evaluate biological potential of bladder tumors.
403. 1986 Traitement du cancer de la prostate metastatique par suppression totale des androgenes: mise a jour des resultats de l'Etude multicentre.
404. 1986 Growth-regulated surface glycoproteins of human bladder cancer: Study of expression and strategies for purification
405. 1986 Progres recents dans l utilisation clinique des anticorps monoclonaux contre les tumeurs vesicales
406. 1986 Clinical implications of monoclonal antibodies to bladder cancer
407. 1986 Clinical and biological studies of metastatic bladder cancer with monoclonal antibodies
408. 1986 Total androgen blockage versus orchiectomy in stage D2 prostate cancer.
409. 1986 Total androgen blockage versus orchiectomy in stage D2 prostate cancer.
410. 1986 New approaches to metastatic cancers with monoclonal antibodies.
411. 1985 Caracterisation de l antigene GP25, un marqueur des cellules endotheliales et des tumeurs vesicales humaines metastatiques
412. 1985 Clinical use of monoclonal antibodies to human bladder cancer in multiparameter flowcytometry studies
413. 1985 Polychimiotherapie de type MVAC dans le traitement des cancers de la vessie un stade avance.
414. 1985 Traitement du cancer de la prostate metastatique par suppression totale des androgenes: resultats un an.
415. 1985 Remplacement vesical par enterocystoplastie apres chirurgie radicale pour cancer de la vessie: evaluations urodynamiques precoces
416. 1985 Rapport preliminaire d'une Etude multicentre sur l'efficacite des antiandrogenes dans le cancer de la prostate metastatique
417. 1985 Impact d une nouvelle chimiotherapie dans le traitement des cancers non seminomateux du testicule.
418. 1985 Early sequential urodynamic evaluations of replacement enterocystoplasties (Camey) after radical surgery for bladder cancer.
419. 1985 Improved analysis of bladder tumor heterogeneity by simultaneous measurement of DNA and monoclonal antibody reactivity using flow cytometry
420. 1984 Sarcomas of the urinary bladder.
421. 1984 Bladder tumor heterogeneity defined by tissue typing with monoclonal antibodies
422. 1984 Monoclonal antibodies to human urinary bladder tumors: characterization and some applications
423. 1984 Characterization and clinical applications of monoclonal antibodies against human bladder cancer.
424. 1984 Automated flow cytometry for characterizing bladder monoclonal antibodies.
425. 1984 Definition of human bladder tumor subsets with monoclonal antibodies to tumor-associated antigens
426. 1984 Study of human bladder cancer by immunopathology and flowcytometry with monoclonal antibodies to tumor-associated antigens.
427. 1984 Phantom tumors on follow-up computerized tomography after retroperitoneal lymph node dissection.
428. 1983 Heterogeneity of human transitional cell carcinoma defined by tissue typing with monoclonal antibodies
429. 1983 Etude des tumeurs vesicales humaines a l aide d anticorps monoclonaux: potentiel pour de nouveaux marqueurs biologiques utiles au clinicien.
430. 1983 Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies
431. 1983 Subclassification of transitional cell neoplasms according to their antigenic phenotype defined by mouse monoclonal antibodies.
432. 1982 Cell surface antigens of human teratocarcinoma cell line analyzed by monoclonal antibodies
433. 1982 Role of prostaglandins E2 and F2a in the physiopathology of postobstructive diuresis.
434. 1981 Enhanced urinary prostaglandins E2 in postobstructive diuresis in humans
435. 1980 Effet benefique des transfusions sanguines et de l identite HLA en transplantation renale.
436. 1980 Elevation des prostaglandines urinaires E2 apres levee d'obstacle chez l'homme.
437. 1976 Modulation de la proliferation lymphocytaire par des facteurs seriques et le lipopolysaccharide (LPS)
438. 1974 Importance du serum dans la proliferation des lymphocytes en presence de Concanavalin A (Con A).
439. 1974 Inhibition of the PHA response by rat thoracic duct lymphocytes.
440. 1973 Separation de cellules T douees de fonctions immunologiques differentes.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.